Overexpression of VEGF and TGF-β1 mRNA in Pap smears correlates with progression of cervical intraepithelial neoplasia to cancer: Implication of YY1 in cervical tumorigenesis and HPV infection

International Journal of Oncology

Volumn 31, Issue 1, 2007, Pages 69-79

  Baritaki, Stavroula ^a,b   Sifakis, Stavros ^c   Huerta Yepez, Sara ^d   Neonakis, Ioannis K ^c   Soufla, Giannoula ^a   Bonavida, Benjamin ^b   Spandidos, Demetrios A ^a  

^a UNIVERSITY OF CRETE   (Greece)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^d INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

Cervical intraepithelial neoplasia; Real time PCR; Transforming growth factor 1; Uterine cervical cancer; Vascular endothelial growth factor; Yin Yang 1

Indexed keywords

MESSENGER RNA; TRANSCRIPTION FACTOR YY1; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; VASCULOTROPIN A; YY1 PROTEIN, HUMAN;

ARTICLE; CELL TRANSFORMATION; DISEASE COURSE; FEMALE; GENE EXPRESSION; GENETICS; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; ISOLATION AND PURIFICATION; METABOLISM; PATHOLOGY; TRANSACTIVATION; UPREGULATION; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX TUMOR; VAGINA SMEAR; VIROLOGY; VIRUS INFECTION;

CELL TRANSFORMATION, NEOPLASTIC; CERVICAL INTRAEPITHELIAL NEOPLASIA; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; PAPILLOMAVIRUS INFECTIONS; RNA, MESSENGER; TRANS-ACTIVATION (GENETICS); TRANSFORMING GROWTH FACTOR BETA1; UP-REGULATION; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YY1 TRANSCRIPTION FACTOR;

EID: 34548555679     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.31.1.69     Document Type: Article

References (49)

1. Soufla G, Sifakis S, Baritaki S, Zafiropoulos A, Koumantakis E and Spandidos DA: VEGF, FGF2, TGFβ1 and TGFβR1 mRNA expression levels correlate with the malignant transformation of the uterine cervix. Cancer Lett 221: 105-118, 2005.
2. Smith-McCune KK and Weidner N: Demonstration and characterization of the angiogenic properties of cervical dysplasia. Cancer Res 54: 800-804, 1994.
3. Munger K and Phelps WC: The human papillomavirus E7 protein as a transforming and transactivating factor. Biochim Biophy Acta 1155: 111-123, 1993.
4. Guidi AJ, Abu-Jawdeh G, Berse B, Jackman RW, Tognazzi K, Dvorak HF and Brown LF: Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia. J Natl Cancer Inst 87: 1237-1245, 1995.
5. Cheng WF, Chen CA, Lee CN, Wei LH, Hsieh FJ and Hsieh CY: Vascular endothelial growth factor and prognosis of cervical carcinoma. Obstet Gynecol 96: 721-726, 2000.
6. Lee IJ, Park KR, Lee KK, et al: Prognostic value of vascular endothelial growth factor in Stage IB carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 54: 768-779, 2002.
7. El-Sherif AM, Seth R, Tighe PJ and Jenkins D: Decreased synthesis and expression of TGF-beta1, beta2, and beta3 in epithelium of HPV 16-positive cervical precancer: a study by microdissection, quantitative RT-PCR, and immunocytochemistry. J Pathol 192: 494-501, 2000.
8. Giannini SL, Al-Saleh W, Piron H, et al: Cytokine expression in squamous intraepithelial lesions of the uterine cervix: implications for the generation of local immunosuppression. Clin Exp Immunol 113: 183-189, 1998.
9. McCartney-Francis NL and Wahl SM: Transforming growth factor beta: a matter of life and death. J Leukoc Biol 55: 401-409, 1994.
10. Shalaby MR and Ammann AJ: Suppression of immune cell function in vitro by recombinant human transforming growth factor-beta. Cell Immunol 112: 343-350, 1988.
11. Aragane Y, Riemann H, Bhardwaj RS, et al: IL-12 is expressed and released by human keratinocytes and epidermoid carcinoma cell lines. J Immunol 153: 5366-5372, 1994.
12. Blobe GC, Schiemann WP and Lodish HF: Role of transforming growth factor beta in human disease. N Engl J Med 342: 1350-1358, 2000.
13. Hobbs K, Negri J, Klinnert M, Rosenwasser LJ and Borish L: Interleukin-10 and transforming growth factor-beta promoter polymorphisms in allergies and asthma. Am J Respir Crit Care Med 158: 1958-1962, 1998.
14. Tsunawaki S, Sporn M, Ding A and Nathan C: Deactivation of macrophages by transforming growth factor-beta. Nature 334: 260-262, 1988.
15. Letterio JJ and Roberts AB: Regulation of immune responses by TGF-beta. Annu Rev Immunol 16: 137-161, 1998.
16. Comerci JT, Runowicz CD, Flanders KC, et al: Altered expression of transforming growth factor-beta 1 in cervical neoplasia as an early biomarker in carcinogenesis of the uterine cervix. Cancer 77: 1107-1114, 1996.
17. Santin AD, Hermonat PL, Hiserodt JC, et al: Differential transforming growth factor-beta secretion in adenocarcinoma and squamous cell carcinoma of the uterine cervix. Gynecol Oncol 64: 477-480, 1997.
18. Tjiong MY, van der Vange N, ter Schegget JS, Burger MP and ten Kate TA: Out, Cytokines in cervicovaginal washing fluid from patients with cervical neoplasia. Cytokine 14: 357-360, 2001.
19. Bergers G and Benjamin LE: Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3: 401-410, 2003.
20. Cheng WF, Chen CA, Lee CN, Chen TM, Hsieh FJ and Hsieh CY: Vascular endothelial growth factor in cervical carcinoma. Obstet Gynecol 93: 761-765, 1999.
21. Tjalma W, Weyler J, Weyn B, et al: The association between vascular endothelial growth factor, microvessel density and clinicopathological features in invasive cervical cancer. Eur J Obstet Gynecol RB 92: 251-257, 2000.
22. Shi Y, Lee JS and Galvin KM: Everything you have ever wanted to know about Yin Yang 1. Biochem Biophys Acta 1332: F49-F66, 1997.
23. Thomas MJ and Seto E: Unlocking the mechanisms of transcription factor YY1: are chromatin modifying enzymes the key? Gene 236: 197-208, 1999.
24. Krippner-Heidenreich A, Walsemann G, Beyrouthy MJ, et al: Caspase-dependent regulation and subcellular redistribution of the transcriptional modulator YY1 during apoptosis. Mol Cell Biol 25: 3704-3714, 2005.
25. Austen M, Luscher B and Luscher-Firzlaff JM: Characterization of the transcriptional regulator YY1. The bipartite transactivation domain is independent of interaction with the TATA box-binding protein, transcription factor IIB, TAFII55, or cAMP-responsive element-binding protein (CPB)-binding protein. J Biol Chem 272: 1709-1717, 1997.
26. Donohoe ME, Zhang X, McGinnis L, Biggers J, Li E and Shi Y: Targeted disruption of mouse Yin Yang 1 transcription factor results in peri-implantation lethality. Mol Cell Biol 19: 7237-7244, 1999.
27. Gordon S, Akopyan G, Garban H and Bonavida B: Transcription factor YY1: structure, function, and therapeutic implications in cancer biology. Oncogene 25: 1125-1142, 2006.
28. Seligson D, Horvath S, Huerta-Yepez S, et al: Expression of transcription factor Yin Yang 1 in prostate cancer. Int J Oncol 27: 131-141, 2005.
29. Flanagan JR: Autologous stimulation of YY1 transcription factor expression: role of an insulin-like growth factor. Cell Growth Differ 2: 185-190, 1995.
30. Santiago FS, Lowe HC, Bobryshev YV and Khachigian LM: Induction of the transcriptional repressor Yin Yang-1 by vascular cell injury. Autocrine/paracrine role of endogenous fibroblast growth factor-2. J Biol Chem 276: 41143-41149, 2001.
31. Dong XP, Stubenrauch F, Beyer-Finkler E and Pfister H: Prevalence of deletions of YY1-binding sites in episomal HPV 16 DNA from cervical cancers. Int J Cancer 58: 803-808, 1994.
32. Benedet JL, Bender H, Jones H III, Ngan HY and Pecorelli S: FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers, FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 70: 209-262, 2000.
33. Lyronis ID, Baritaki S, Bizakis I, Tsardi M and Spandidos DA: Evaluation of the prevalence of human papillomavirus and Epstein-Barr virus in esophageal squamous cell carcinomas. Int J Biol Markers 20: 5-10, 2005.
34. Dokianakis DN, Sourvinos G, Sakkas S, Athanasiadou E and Spandidos DA: Detection of HPV and ras gene mutations in cervical smears from female genital lesions. Oncol Rep 5: 1195-1198, 1998.
35. Dokianakis DN, Papaefthimiou M, Tsiveleka A and Spandidos DA: High prevalence of HPV18 in correlation with ras gene mutations and clinicopathological parameters in cervical cancer studied from stained cytological smears. Oncol Rep 6: 1327-1331, 1999.
36. Obermair A, Bancher-Todesca D, Bilgi S, Kaider A, Kohlberger P and Mullauer-Ertl S: Correlation of vascular endothelial growth factor expression and microvessel density in cervical intra-epithelial neoplasia. J Natl Cancer Inst 89: 1212-1217, 1997.
37. Ferrara N: Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25: 581-611, 2004.
38. Abulafia O, Triest WE and Sherer DM: Angiogenesis in malignancies of the female genital tract. Gynecol Oncol 72: 220-231, 1999.
39. Derynck R, Akhurst RJ and Balmain A: TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 29: 117-129, 2001.
40. Moustakas A, Pardali K, Gaal A and Heldin CH: Mechanisms of TGF-beta signaling in regulation of cell growth and differentiation. Immunol Lett 82: 85-91, 2002.
41. Hazelbag S, Fleuren GJ, Baelde JJ, Schuuring E, Kenter GG and Gorter A: Cytokine profile of cervical cancer cells. Gynecol Oncol 83: 235-243, 2001.
42. Silverman ES, Palmer LJ, Subramaniam V, et al: Transforming growth factor-beta1 promoter polymorphism C-509T is associated with asthma. Am J Respir Crit Care Med 169: 214-219, 2004.
43. Grainger DJ, Heathcote K, Chiano M, et al: Genetic control of the circulating concentration of transforming growth factor type beta1. Hum Mol Genet 8: 93-97, 1999.
44. Kurisaki K, Kurisaki A, Valcourt U, et al: Nuclear factor YY1 inhibits transforming growth factor beta- and bone morphogenetic protein-induced cell differentiation. Mol Cell Biol 23: 4494-4510, 2003.
45. Romanczuk H, Villa LL and Schlegel R: The viral transcriptional regulatory region upstream of the E6 and E7 genes is a major determinant of the differential immortalization activities of human papillomavirus types 16 and 18. J Virol 65: 2739-2744, 1991.
46. Rose B, Steger G, Dong XP, et al: Point mutations in SP1 motifs in the upstream regulatory region of human papillomavirus type 18 isolates from cervical cancers increase promoter activity. J Gen Virol 79: 1659-1663, 1998.
47. Villa LL and Schlegel R: Differences in transformation activity between HPV18 and HPV16 map to the viral LCR-E6-E7 region. Virology 181: 374-377, 1991.
48. Hoppe-Seyler F and Butz K: Cellular control of human papillomavirus oncogene transcription. Mol Carcinog 10: 134-141, 1994.
49. Dong XP and Pfister H: Overlapping YY1- and aberrant SP1-binding sites proximal to the early promoter of human papillomavirus type 16. J Gen Virol 80: 2097-2101, 1999.